These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20560842)

  • 1. Behavioral effects of d-amphetamine in humans: influence of subclinical levels of inattention and hyperactivity.
    Sevak RJ; Stoops WW; Rush CR
    Am J Drug Alcohol Abuse; 2010 Jul; 36(4):220-7. PubMed ID: 20560842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxazepam does not modulate the behavioral effects of d-amphetamine in humans.
    Lile JA; Stoops WW; Wagner FP; Glaser PE; Rush CR
    Pharmacol Biochem Behav; 2005 Oct; 82(2):270-9. PubMed ID: 16182353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual differences in responses to ethanol and d-amphetamine: a within-subject study.
    Holdstock L; de Wit H
    Alcohol Clin Exp Res; 2001 Apr; 25(4):540-8. PubMed ID: 11329494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.
    Konstenius M; Jayaram-Lindström N; Beck O; Franck J
    Drug Alcohol Depend; 2010 Apr; 108(1-2):130-3. PubMed ID: 20015599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults.
    Makris AP; Rush CR; Frederich RC; Taylor AC; Kelly TH
    Exp Clin Psychopharmacol; 2007 Apr; 15(2):123-33. PubMed ID: 17469936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attention-Deficit Hyperactivity Disorder (ADHD) symptoms and smoking patterns among participants in a smoking-cessation program.
    Lerman C; Audrain J; Tercyak K; Hawk LW; Bush A; Crystal-Mansour S; Rose C; Niaura R; Epstein LH
    Nicotine Tob Res; 2001 Nov; 3(4):353-9. PubMed ID: 11694203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.
    Jasinski DR; Krishnan S
    J Psychopharmacol; 2009 Jun; 23(4):419-27. PubMed ID: 19329547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD.
    Pearson DA; Santos CW; Roache JD; Casat CD; Loveland KA; Lachar D; Lane DM; Faria LP; Cleveland LA
    J Am Acad Child Adolesc Psychiatry; 2003 Feb; 42(2):209-16. PubMed ID: 12544181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
    Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.